Abstract
Children with end stage kidney disease (ESKD) face a lifetime of complex medical care, alternating between maintenance chronic dialysis and kidney transplantation. As for adults, kidney transplantation has emerged as the optimal treatment of ESKD for children and provides important quality of life and survival advantages. Though transplantation is the preferred therapy, lifetime exposure to immunosuppression among children with ESKD is associated with increased morbidity including an increased risk of cancer. Following pediatric kidney transplantation, cancer events occurring during childhood or young adulthood can be divided into two broad categories: post-transplant lymphoproliferative disorders (PTLD) and non-lymphoproliferative solid tumors. This review provides an overview of cancer incidence, types, outcomes, and preventive strategies in this population.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
